COST-EFFECTIVENESS COMPARISON OF BOTULINUM TOXIN TYPE A PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE IN THE TREATMENT OF IDIOPATHIC OVERACTIVE BLADDER WITH URINARY INCONTINENCE AMONG PATIENTS NOT ADEQUATELY MANAGED BY ANTICHOLINERGIC THERAPY IN FRANCE

被引：1
|
作者：
Ruffion, A. [1 ]
Velard, M. [2 ]
Loveman, C. [3 ]
Khalaf, K. [4 ]
Roze, S. [5 ]
Pignata, M. [5 ]
Stanisic, S. [6 ]
Lister, J. [7 ]
机构：
[1] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France
[2] Allergan France SAS, Courbevoie, France
[3] Allergan Holdings Ltd, Marlow, Bucks, England
[4] Allergan Pharmaceut Inc, Irvine, CA USA
[5] HEVA HEOR, Lyon, France
[6] LASER Grp, Milan, Italy
[7] LASER ANALYT, Lorrach, Germany
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.1330
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PUK22
引用
收藏
页码：A470 / A470
页数：1
相关论文
共 50 条
  • [21] Correction to: Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US
    Hardik Goswami
    Adnan Alsumali
    Yiling Jiang
    Matthias Schindler
    Elizabeth R. Duke
    Joshua Cohen
    Andrew Briggs
    Amy Puenpatom
    PharmacoEconomics, 2023, 41 : 605 - 605
  • [22] COST-EFFECTIVENESS OF IMATINIB AS ADJUVANT TREATMENT FOR RESECTED GASTROINTESTINAL STROMAL TUMORS (GIST) VERSUS BEST SUPPORTIVE CARE: CANADIAN PERSPECTIVE
    El Ouagari, K.
    Pawar, V
    Coombs, J.
    Rubin, J.
    VALUE IN HEALTH, 2010, 13 (07) : A270 - A270
  • [23] Economic evaluation of sunitinib versus pazopanib and best supportive care for the treatment of metastatic renal cell carcinoma in Chile: cost-effectiveness analysis and a mixed treatment comparison
    Vargas, C.
    Balmaceda, C.
    Rodriguez, F.
    Rojas, R.
    Giglio, A.
    Espinoza, M. A.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2019, 19 (05) : 609 - 617
  • [24] THE COST EFFECTIVENESS OF CETUXIMAB PLUS BEST SUPPORTIVE CARE (BSC) VERSUS BSC ALONE IN LAST LINE FOR KRAS WILD TYPE METASTATIC COLORECTAL CANCER PATIENT POPULATION
    Chaugule, S.
    Hay, J.
    VALUE IN HEALTH, 2012, 15 (04) : A219 - A219
  • [25] Cost-Effectiveness Analysis of Ranibizumab versus Verteporfin Photodynamic Therapy, Pegaptanib Sodium, and Best Supportive Care for the Treatment of Age-Related Macular Degeneration in Greece
    Athanasakis, Kostas
    Fragoulakis, Vasilios
    Tsiantou, Vasiliki
    Masaoutis, Panagiotis
    Maniadakis, Nikolaos
    Kyriopoulos, John
    CLINICAL THERAPEUTICS, 2012, 34 (02) : 446 - 456
  • [26] COST-EFFECTIVENESS ANALYSIS OF A DIGITAL HEALTH APPLICATION (DIGA) PLUS BEST SUPPORTIVE CARE (BSC) COMPARED TO BSC IN GERMAN EPISODIC MIGRAINE PATIENTS
    Walter, E.
    Wegner, S.
    Burziwoda, D.
    VALUE IN HEALTH, 2022, 25 (12) : S129 - S129
  • [27] COST-EFFECTIVENESS ANALYSIS OF AVELUMAB PLUS BEST SUPPORTIVE CARE (BSC) AS FIRST-LINE MAINTENANCE TREATMENT IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA (LA/MUC) IN FRANCE
    Plessala, I
    Cawston, H.
    Roiz, J.
    Xiao, Y.
    Kearney, M.
    Chang, J.
    Porte, F.
    Granghaud, A.
    Morel, A.
    Ravaud, A.
    Loriot, Y.
    Thiery-Vuillemin, A.
    Levy, P.
    VALUE IN HEALTH, 2022, 25 (12) : S113 - S113
  • [28] Cost-effectiveness of ofatumumab in comparison with other disease modifying therapies and best supportive care for the treatment of relapsing-remitting multiple sclerosis in Canada
    Mouallif, S.
    Thomas, K.
    Adlard, N.
    Cooney, P.
    Blanchette, F.
    Patel, B.
    Baharnoori, M.
    Bhan, V.
    Clift, F.
    Grima, D.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 311 - 311
  • [29] SACRAL NERVE STIMULATION AND BOTULINUM TOXIN A FOR THE TREATMENT OF REFRACTORY IDIOPATHIC OVERACTIVE BLADDER: AN INDEPENDENT COST-EFFECTIVENESS ANALYSIS IN THE PERSPECTIVE OF ITALIAN NATIONAL HEALTH CARE SERVICE
    Bertapelle, M. P.
    D'Ausilio, A.
    Vottero, M.
    Del Popolo, G.
    Giannantoni, A.
    Mencarini, M.
    Ostardo, E.
    Spinelli, M.
    NEUROUROLOGY AND URODYNAMICS, 2013, 32 (06) : 688 - 688
  • [30] Comparison of best supportive care, CHOP, or R-CHOP for treatment of diffuse large B-cell lymphoma in Malawi: a cost-effectiveness analysis
    Painschab, Matthew S.
    Kohler, Racquel
    Kimani, Stephen
    Mhango, Wilberforce
    Kaimila, Bongani
    Zuze, Takondwa
    Mithi, Victor
    Kasonkanji, Edwards
    Mumba, Noel
    Nyasosela, Richard
    Wheeler, Stephanie
    Gopal, Satish
    LANCET GLOBAL HEALTH, 2021, 9 (09): : E1305 - E1313
12345